Literature DB >> 8738763

Population pharmacokinetics of caffeine in neonates and young infants.

A H Thomson1, S Kerr, S Wright.   

Abstract

The population pharmacokinetics of caffeine were investigated in 60 neonates and young infants using data collected during routine therapeutic drug monitoring. Clearance was influenced by body weight and postnatal age, and increased in the presence of dexamethasone. No clinical factors were identified that influenced volume of distribution. The population pharmacokinetic parameter estimates were then tested prospectively in a further 20 neonates. Although they produced unbiased results, the dexamethasone effect could not be identified. A final analysis using all 80 patients found clearance (L/day) = 0.14 x weight (kg) + 0.0024 x postnatal age (days) (+/- 20%) and volume of distribution = 0.82 L (+/- 24%). Simulations based on these results indicated that the current dosage guidelines of 20 mg/kg loading dose of caffeine citrate followed by a 5 mg/kg/day maintenance dose should achieve concentrations within the traditional target range in > 70% of neonates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738763     DOI: 10.1097/00007691-199606000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates.

Authors:  Sandrine Micallef; Billy Amzal; Véronique Bach; Karen Chardon; Pierre Tourneux; Frédéric Y Bois
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

Review 3.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants.

Authors:  Parul Patel; Hussain Mulla; Venkatesh Kairamkonda; Neil Spooner; Sonya Gade; Oscar Della Pasqua; David J Field; Hitesh C Pandya
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Apnea of prematurity: caffeine dose optimization.

Authors:  Suzanne J Francart; Megan K Allen; Jennifer Stegall-Zanation
Journal:  J Pediatr Pharmacol Ther       Date:  2013-01

7.  Caffeine in apnoeic Asian neonates: a sparse data analysis.

Authors:  How Sung Lee; Yok Moi Khoo; Yazmin Chirino-Barcelo; Kim Leong Tan; Dorothy Ong
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

8.  Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy.

Authors:  Nicole R Dobson; Xiaoxi Liu; Lawrence M Rhein; Robert A Darnall; Michael J Corwin; Betty L McEntire; Robert M Ward; Laura P James; Catherine M T Sherwin; Timothy C Heeren; Carl E Hunt
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

Review 9.  Population pharmacokinetic analysis during the first 2 years of life: an overview.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

10.  Ontogeny of midazolam glucuronidation in preterm infants.

Authors:  Saskia N de Wildt; Greg L Kearns; Darryl J Murry; Gideon Koren; John N van den Anker
Journal:  Eur J Clin Pharmacol       Date:  2009-10-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.